Biotech entity
pharma is the sole category represented across all 1 tracked stories. I-Mab is most often covered alongside Brooklyn Investment Group, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. I-Mab appears in 1 tracked Biotech story from August 22, 2026.
Last mentioned: 1d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. I-Mab is most often covered alongside Brooklyn Investment Group, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. I-Mab appears in 1 tracked Biotech story from August 22, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 3 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering I-Mab. Shared-story counts are live from our verified record — not editorial picks.
I-Mab, a clinical-stage oncology and immunology biotech, reported a $(0.16) quarterly EPS on Aug 20. With shares at $1.91, H.C. Wainwright's reiterated $9 target implies massive upside, though Weiss remains bearish. Institutional ownership sits at 38.38%.
Source: Bbns · Ticker Report
I-Mab is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
